Pharmacologic Characterization of ALD403, a Potent Neutralizing Humanized Monoclonal Antibody Against the Calcitonin Gene-Related Peptide
Leon F Garcia-Martinez,Carol J Raport,Ethan W Ojala,Benjamin Dutzar,Katie Anderson,Erica Stewart,Brian Kovacevich,Brian Baker,Jens Billgren,Michelle Scalley-Kim,Charlie Karasek,Dan Allison,John A Latham,Leon F. Garcia-Martinez,Carol J. Raport,Ethan W. Ojala,John A. Latham
DOI: https://doi.org/10.1124/jpet.119.264671
2020-05-04
Journal of Pharmacology and Experimental Therapeutics
Abstract:<p>ALD403 is a genetically engineered, humanized immunoglobulin G1 monoclonal antibody that inhibits the action of human calcitonin gene-related peptide (CGRP). Clinical trial data indicate that ALD403 is effective as a preventive therapy for migraine and has an acceptable safety profile. For preclinical characterization of ALD403, rabbit antibodies targeting <i>α</i>-CGRP were humanized and modified to eliminate fragment crystallizable (Fc) receptor (FcR) and complement interactions. The ability of ALD403 to inhibit CGRP-induced cAMP production was assessed using a cAMP bioassay (Meso Scale Discovery). The IC<sub>50</sub> for inhibition of cAMP release was 434 and 288 pM with the rabbit-human chimera antibody and the humanized ALD403, respectively. ALD403 inhibited <i>α</i>-CGRP binding with an IC<sub>50</sub> of 4.7 x 10<sup>–11</sup> and 1.2 x 10<sup>–10</sup> M for the <i>α</i>-CGRP and AMY1 receptors, respectively. ALD403 did not induce antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity and did not stably interact with any of the FcR mediating these functions, exhibiting only weak binding to FcRI. ALD403 significantly lowered capsaicin-induced blood flow responses in rodents at all time points starting at 5 minutes postapplication in a dose-dependent manner. In conclusion, ALD403 is a potent functional ligand inhibitor of <i>α</i>-CGRP-driven pharmacology.</p>SIGNIFICANCE STATEMENT<p>α-Calcitonin gene-related peptide blockade by ALD403 was assessed via radiolabeled ligand displacement, in vitro inhibition of cell signaling, and in vivo inhibition of capsaicin-induced vasodilation. Lack of engagement of fragment crystallizable–mediated immune-effector functions by ALD403 was shown.</p>
pharmacology & pharmacy